Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD 11.50
-0.08 (-0.69%)
Feb 11, 2026, 4:00 PM EST
Eupraxia Pharmaceuticals Market Cap
Eupraxia Pharmaceuticals has a market cap or net worth of CAD 582.46 million as of February 11, 2026. Its market cap has increased by 277.62% in one year.
Market Cap
582.46M
Enterprise Value
500.74M
Revenue
n/a
Ranking
n/a
PE Ratio
n/a
Stock Price
11.50
Market Cap Chart
Since March 9, 2021, Eupraxia Pharmaceuticals's market cap has increased from 78.01M to 582.46M, an increase of 646.68%. That is a compound annual growth rate of 50.37%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 10, 2026 | 586.51M | 12.21% |
| Dec 31, 2025 | 522.69M | 225.34% |
| Dec 31, 2024 | 160.66M | 9.74% |
| Dec 29, 2023 | 146.40M | 85.76% |
| Dec 30, 2022 | 78.81M | 125.87% |
| Dec 31, 2021 | 34.89M | -55.27% |
| Mar 9, 2021 | 78.01M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Bright Minds Biosciences | 1.02B |
| NervGen Pharma | 426.12M |
| Satellos Bioscience | 319.63M |
| Helix BioPharma | 139.77M |
| ME Therapeutics Holdings | 75.12M |
| Medicenna Therapeutics | 68.40M |
| Sharp Therapeutics | 66.17M |
| NurExone Biologic | 61.66M |